Indications and Purposes
| 1 Indications And Usage Brineura Is Indicated To Slow The Loss Of Ambulation In Symptomatic Pediatric Patients 3 Years Of Age And Older With Late Infantile Neuronal Ceroid Lipofuscinosis Type 2 (Cln2), Also Known As Tripeptidyl Peptidase 1 (Tpp1) Deficiency. Brineura Is A Hydrolytic Lysosomal N-Terminal Tripeptidyl Peptidase Indicated To Slow The Loss Of Ambulation In Symptomatic Pediatric Patients 3 Years Of Age And Older With Late Infantile Neuronal Ceroid Lipofuscinosis Type 2 (Cln2), Also Known As Tripeptidyl Peptidase 1 (Tpp1) Deficiency. ( 1 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Cerliponase Alfa |